Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Studies of the oral bioavailability of alendronate.

Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG.

Clin Pharmacol Ther. 1995 Sep;58(3):288-98.

PMID:
7554702
2.

Clinical pharmacology of alendronate sodium.

Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG.

Osteoporos Int. 1993;3 Suppl 3:S13-6.

PMID:
8298197
4.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
5.

Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.

Kakuda TN, Falcon RW.

Pharmacotherapy. 2006 Aug;26(8):1060-8.

PMID:
16863482
6.

Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.

Rhim SY, Park JH, Park YS, Lee MH, Kim DS, Shaw LM, Yang SC, Kang JS.

Clin Ther. 2009 May;31(5):1037-45. doi: 10.1016/j.clinthera.2009.05.001.

PMID:
19539104
7.

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E.

Joint Bone Spine. 2008 May;75(3):303-10. Epub 2007 Oct 22.

PMID:
18069036
8.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

Aging (Milano). 2000 Feb;12(1):1-12.

PMID:
10746426
9.

Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers.

Lange D, Pavao JH, Wu J, Klausner M.

J Clin Pharmacol. 1997 Jun;37(6):535-40.

PMID:
9208361
10.

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D.

Curr Med Res Opin. 2005 Dec;21(12):1895-903.

PMID:
16368038
11.

The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.

Barditch-Crovo PA, Petty BG, Gambertoglio J, Nerhood LJ, Kuwahara S, Hafner R, Lietman PS, Kornhauser DM.

Antiviral Res. 1998 Jun;38(3):209-12.

PMID:
9754889
12.

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.

Lanza F, Sahba B, Schwartz H, Winograd S, Torosis J, Quan H, Reyes R, Musliner T, Daifotis A, Leung A.

Am J Gastroenterol. 2002 Jan;97(1):58-64.

PMID:
11808969
13.

Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose.

Bekersky I, Dressler D, Mekki Q.

J Clin Pharmacol. 2001 Mar;41(3):289-97.

PMID:
11269569
14.

Intravenous bisphosphonate therapy for osteoporosis: where do we stand?

Bone HG, Schurr W.

Curr Osteoporos Rep. 2004 Mar;2(1):24-30. Review.

PMID:
16036079
15.

Alendronate/colecalciferol.

Reynolds NA, Curran MP.

Treat Endocrinol. 2005;4(6):371-7; discussion 379. Review.

PMID:
16318403
17.
18.

Differences in persistence among different weekly oral bisphosphonate medications.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Aug;20(8):1369-76. doi: 10.1007/s00198-008-0795-8. Epub 2008 Nov 20.

PMID:
19020921
19.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
20.

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.

Cramer JA, Amonkar MM, Hebborn A, Altman R.

Curr Med Res Opin. 2005 Sep;21(9):1453-60.

PMID:
16197664
Items per page

Supplemental Content

Write to the Help Desk